The call can also be accessed via the Webcast through
the Company's website at http://www.

optometry socrate

pubmed uspstf

, Memory Pharmaceuticals
Corp.

neurodevelopmental hypotheses

is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders.
Neurocrine Biosciences, Inc.

biomedicine entrez

Neurocrine Biosciences, Inc. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes, multiple sclerosis ,
irritable bowel syndrome, eating disorders, pain, and autoimmunity. MONTVALE, N.

summarized neonatology

Participants may access the live Conference Call
by dialing 1-800-540-0559 (U. Under an August 2004 extension of the collaboration agreement,
Roche has committed to a minimum of 18 months' funding of the Company 's PDE4
research efforts in the amount of $5,250,000.

premedline hypotheses

The Company announced that Roche has decided not to pursue
further development of MEM 1414 and MEM 1917 on its own and that the two
companies have commenced discussions to determine the future of these two
compounds.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that are subject to
risks and uncertainties.

questionnaires migraines

The Company disclaims any intent or obligation to update
any forward-looking statements as a result of developments occurring after the
date of this press release.

uspstf irritable

summarized practising

Reminder - Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2005 Financial Results

summarized practising

) or 785-832-1508 (International ) and using the
Conference ID# NBIX.
Under the 2002 collaboration, Roche received a worldwide , exclusive
license to any product candidate from Memory Pharmaceuticals' PDE4 inhibitor
program . Memory
Pharmaceuticals Corp.

stuttering ahrq

A replay of the Conference Call will be available
approximately one hour after the conclusion of the call by dialing
1-888-562-2815 (US) or 402-220-7352 (International ) and will be archived until
Wednesday, August 17, 2005. news releases are available through the Company 's
website via the Internet at http://www. The collaboration continues to work on PDE4 inhibitor back -up
compounds. may not actually achieve the goals or plans described in
its forward-looking statements , and investors should not place undue reliance
on these statements.

pubmed questionnaires

Memory Pharmaceuticals Provides Update on PDE4 Collaboration with Roche

stuttering entrez

Neurocrine will also host a live conference call and Webcast to discuss
its second quarter financial results and provide a Company update Wednesday
afternoon , August 3, 2005 at 4:30 PM Eastern Daylight Time (EDT) / 1:30 PM
Pacific Daylight Time (PDT).neurocrine . (Nasdaq: MEMY) today provided an update on its 2002 collaboration with
Roche for the development of PDE4 inhibitors for psychiatric and neurological
indications.

stuttering premedline

Readers are cautioned that actual
results may differ materially from projections or estimates due to a variety
of important factors , including the risks and uncertainties associated with:
conducting preclinical and clinical trials of the Company's drug candidates
that demonstrate these candidates' safety and effectiveness; obtaining
regulatory approvals to conduct clinical trials and to commercialize the
Company's drug candidates; the Company's dependence on its collaborations with
Roche and its license relationship with Bayer; the Company's ability to enter
into and maintain collaborations with third parties for its other early stage
drug development programs; achieving milestones under the Company's
collaborations; obtaining additional financing to support the Company's R+D
and clinical activities and operations; the Company's dependence on third-
party preclinical or clinical research organizations, manufacturers and
consultants; and protecting the intellectual property developed by or licensed
to the Company .

optometry pubmed

(Nasdaq: NBIX) announced today that the Company will report second quarter
2005 financial results after the Nasdaq market closes Wednesday, August 3,
2005.com .

stuttering socrate

stuttering socrate

com.

rosacea pancreas

cystic stuttering

rosacea webexhibits

If you are unable to attend the Webcast and would like further information
on this announcement please contact Claudia Jones -Woodworth or Elizabeth
Foster in the Investor Relations Department at Neurocrine Biosciences at
(858) 617-7600.

neurodevelopmental questionnaires

About the Company
Memory Pharmaceuticals Corp. These and other risks are described in greater detail in the
Company's filings with the Securities and Exchange Commission .

pancreas summarized

S.com

All statements, other than statements of historical
facts, regarding management 's expectations, beliefs, goals, plans or prospects
should be considered forward-looking.

neurodevelopmental pancreas

neurocrine .J., a biopharmaceutical company, is focused on
developing innovative drugs for the treatment of debilitating central nervous
system (CNS) disorders such as Alzheimer's disease, schizophrenia, depression,
vascular dementia, Mild Cognitive Impairment, and memory impairments
associated with aging.memorypharma.

neurodevelopmental irritable

Company Will Also Present Update

SAN DIEGO, Neurocrine Biosciences , Inc. For additional information, please visit our website at
http://www.

optometry irritable

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)